PolarityTE, Inc. (COOL)’s Trend Up, Especially After Today’s Strong Session

February 15, 2018 - By Adrian Erickson

The stock of PolarityTE, Inc. (NASDAQ:COOL) is a huge mover today! The stock increased 14.46% or $2.94 during the last trading session, reaching $23.24. About 412,113 shares traded or 243.67% up from the average. PolarityTE, Inc. (NASDAQ:COOL) has risen 140.86% since February 15, 2017 and is uptrending. It has outperformed by 124.16% the S&P500.
The move comes after 7 months positive chart setup for the $157.18M company. It was reported on Feb, 15 by Barchart.com. We have $24.17 PT which if reached, will make NASDAQ:COOL worth $6.29M more.

PolarityTE, Inc. (NASDAQ:COOL) Ratings Coverage

Among 2 analysts covering Majesco Entertainment (NASDAQ:COOL), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Majesco Entertainment had 3 analyst reports since August 18, 2015 according to SRatingsIntel. Zacks upgraded the stock to “Sell” rating in Tuesday, August 18 report. The rating was initiated by Cantor Fitzgerald with “Buy” on Wednesday, February 14. The rating was initiated by Maxim Group on Thursday, August 27 with “Buy”.

More notable recent PolarityTE, Inc. (NASDAQ:COOL) news were published by: Seekingalpha.com which released: “PolarityTE: Investors Beware” on December 07, 2017, also Marketwired.com with their article: “PolarityTEâ„¢ Inc. Stockholders Approve Merger” published on March 13, 2017, Marketwatch.com published: “PolarityTE Inc.” on March 31, 2017. More interesting news about PolarityTE, Inc. (NASDAQ:COOL) were released by: Marketwired.com and their article: “PolarityTEâ„¢, Inc. Recruits Key Additions to Management” published on April 18, 2017 as well as Seekingalpha.com‘s news article titled: “PolarityTE: The Cool Shift To Regenerative Medicine” with publication date: April 07, 2017.

PolarityTE, Inc. operates as commercial-stage biotechnology and regenerative biomaterials firm in the United States. The company has market cap of $157.18 million. The firm focuses on discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. It currently has negative earnings. The Company’s PolarityTE platform would be able to provide transform tissue regeneration, including potential regeneration of multiple tissue substrates, such as skin, bone, muscle, fat, cartilage, nerves, and blood vessels, as well as neural elements, solid and hollow organ composite tissue systems.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.